Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1988 Jan;56(1):24–27. doi: 10.1128/iai.56.1.24-27.1988

Partial characterization of the enzymatic activity associated with the binary toxin (type C2) produced by Clostridium botulinum.

L L Simpson 1, H Zepeda 1, I Ohishi 1
PMCID: PMC259227  PMID: 3121511

Abstract

Clostridium botulinum produces a binary toxin that possesses a heavy chain (approximately 100,000 daltons) and a light chain (approximately 50,000 daltons). The heavy chain is a binding component that directs the toxin to vulnerable cells, and the light chain is an enzyme that has mono(ADP-ribosyl)ating activity. A number of experiments have been done to help characterize the enzymatic activity of the toxin. The data reveal that the enzyme has a pH optimum within the range of 7.0 to 8.0. It is not inhibited or stimulated by physiological concentrations of sodium, potassium, calcium, or magnesium. The enzyme is inhibited by high concentrations of salt, however, as well as high concentrations of nicotinamide, thymidine, theophylline, and histamine; and it is stimulated by histone and lysolecithin. Boiling irreversibly denatures the light chain of the toxin, but denaturation caused by guanidine and urea is substantially reversible. Enzymatic activity is not altered by short exposure to lysosomal proteases, including cathepsin B, cathepsin H, dipeptidyl aminopeptidase, and catheptic carboxypeptidase B.

Full text

PDF
24

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aktories K., Bärmann M., Ohishi I., Tsuyama S., Jakobs K. H., Habermann E. Botulinum C2 toxin ADP-ribosylates actin. Nature. 1986 Jul 24;322(6077):390–392. doi: 10.1038/322390a0. [DOI] [PubMed] [Google Scholar]
  2. Brown P. R., Krstulovic A. M., Hartwick R. A. Current state of the art in the HPLC analyses of free nucleotides, nucleosides, and bases in biological fluids. Adv Chromatogr. 1980;18:101–138. [PubMed] [Google Scholar]
  3. Cassel D., Pfeuffer T. Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system. Proc Natl Acad Sci U S A. 1978 Jun;75(6):2669–2673. doi: 10.1073/pnas.75.6.2669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chung D. W., Collier R. J. The mechanism of ADP-ribosylation of elongation factor 2 catalyzed by fragment A from diphtheria toxin. Biochim Biophys Acta. 1977 Aug 11;483(2):248–257. doi: 10.1016/0005-2744(77)90053-5. [DOI] [PubMed] [Google Scholar]
  5. Cukor G., Solotorovsky M., Kuchler R. J. Biological activity of heated diphtheria toxin. J Bacteriol. 1973 Jul;115(1):277–283. doi: 10.1128/jb.115.1.277-283.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Florin I., Thelestam M. ADP-ribosylation in cultured cells treated with Clostridium difficile toxin B. Biochem Biophys Res Commun. 1986 Aug 29;139(1):64–70. doi: 10.1016/s0006-291x(86)80080-8. [DOI] [PubMed] [Google Scholar]
  7. Gill D. M., Meren R. ADP-ribosylation of membrane proteins catalyzed by cholera toxin: basis of the activation of adenylate cyclase. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3050–3054. doi: 10.1073/pnas.75.7.3050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Honjo T., Nishizuka Y., Kato I., Hayaishi O. Adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis by diphtheria toxin. J Biol Chem. 1971 Jul 10;246(13):4251–4260. [PubMed] [Google Scholar]
  9. Iglewski B. H., Kabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,. Proc Natl Acad Sci U S A. 1975 Jun;72(6):2284–2288. doi: 10.1073/pnas.72.6.2284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Iwasaki M., Ohishi I., Sakaguchi G. Evidence that botulinum C2 toxin has two dissimilar components. Infect Immun. 1980 Aug;29(2):390–394. doi: 10.1128/iai.29.2.390-394.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kaslow H. R., Lim L. K., Moss J., Lesikar D. D. Structure-activity analysis of the activation of pertussis toxin. Biochemistry. 1987 Jan 13;26(1):123–127. doi: 10.1021/bi00375a018. [DOI] [PubMed] [Google Scholar]
  12. Katada T., Ui M. Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc Natl Acad Sci U S A. 1982 May;79(10):3129–3133. doi: 10.1073/pnas.79.10.3129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lee H., Iglewski W. J. Cellular ADP-ribosyltransferase with the same mechanism of action as diphtheria toxin and Pseudomonas toxin A. Proc Natl Acad Sci U S A. 1984 May;81(9):2703–2707. doi: 10.1073/pnas.81.9.2703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mekalanos J. J., Collier R. J., Romig W. R. Purification of cholera toxin and its subunits: new methods of preparation and the use of hypertoxinogenic mutants. Infect Immun. 1978 May;20(2):552–558. doi: 10.1128/iai.20.2.552-558.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Moss J., Osborne J. C., Jr, Stanley S. J. Activation of an erythrocyte NAD:arginine ADP-ribosyltransferase by lysolecithin and nonionic and zwitterionic detergents. Biochemistry. 1984 Mar 27;23(7):1353–1357. doi: 10.1021/bi00302a003. [DOI] [PubMed] [Google Scholar]
  16. Moss J., Richardson S. H. Activation of adenylate cyclase by heat-labile Escherichia coli enterotoxin. Evidence for ADP-ribosyltransferase activity similar to that of choleragen. J Clin Invest. 1978 Aug;62(2):281–285. doi: 10.1172/JCI109127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Moss J., Stanley S. J. Histone-dependent and histone-independent forms of an ADP-ribosyltransferase from human and turkey erythrocytes. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4809–4812. doi: 10.1073/pnas.78.8.4809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Moss J., Stanley S. J., Osborne J. C., Jr Activation of an NAD:arginine ADP-ribosyltransferase by histone. J Biol Chem. 1982 Feb 25;257(4):1660–1663. [PubMed] [Google Scholar]
  19. Moss J., Stanley S. J., Watkins P. A., Burns D. L., Manclark C. R., Kaslow H. R., Hewlett E. L. Stimulation of the thiol-dependent ADP-ribosyltransferase and NAD glycohydrolase activities of Bordetella pertussis toxin by adenine nucleotides, phospholipids, and detergents. Biochemistry. 1986 May 6;25(9):2720–2725. doi: 10.1021/bi00357a066. [DOI] [PubMed] [Google Scholar]
  20. Moss J., Vaughan M. Isolation of an avian erythrocyte protein possessing ADP-ribosyltransferase activity and capable of activating adenylate cyclase. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3621–3624. doi: 10.1073/pnas.75.8.3621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ohishi I., Iwasaki M., Sakaguchi G. Purification and characterization of two components of botulinum C2 toxin. Infect Immun. 1980 Dec;30(3):668–673. doi: 10.1128/iai.30.3.668-673.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ohishi I., Miyake M. Binding of the two components of C2 toxin to epithelial cells and brush borders of mouse intestine. Infect Immun. 1985 Jun;48(3):769–775. doi: 10.1128/iai.48.3.769-775.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ohishi I. NAD-glycohydrolase activity of botulinum C2 toxin: a possible role of component I in the mode of action of the toxin. J Biochem. 1986 Aug;100(2):407–413. doi: 10.1093/oxfordjournals.jbchem.a121728. [DOI] [PubMed] [Google Scholar]
  24. Ohishi I., Tsuyama S. ADP-ribosylation of nonmuscle actin with component I of C2 toxin. Biochem Biophys Res Commun. 1986 Apr 29;136(2):802–806. doi: 10.1016/0006-291x(86)90511-5. [DOI] [PubMed] [Google Scholar]
  25. Simpson L. L. A comparison of the pharmacological properties of Clostridium botulinum type C1 and C2 toxins. J Pharmacol Exp Ther. 1982 Dec;223(3):695–701. [PubMed] [Google Scholar]
  26. Simpson L. L. Molecular basis for the pharmacological actions of Clostridium botulinum type C2 toxin. J Pharmacol Exp Ther. 1984 Sep;230(3):665–669. [PubMed] [Google Scholar]
  27. Simpson L. L. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol. 1986;26:427–453. doi: 10.1146/annurev.pa.26.040186.002235. [DOI] [PubMed] [Google Scholar]
  28. Simpson L. L., Stiles B. G., Zepeda H. H., Wilkins T. D. Molecular basis for the pathological actions of Clostridium perfringens iota toxin. Infect Immun. 1987 Jan;55(1):118–122. doi: 10.1128/iai.55.1.118-122.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sitikov A. S., Davydova E. K., Ovchinnikov L. P. Endogenous ADP-ribosylation of elongation factor 2 in polyribosome fraction of rabbit reticulocytes. FEBS Lett. 1984 Oct 15;176(1):261–263. doi: 10.1016/0014-5793(84)80953-9. [DOI] [PubMed] [Google Scholar]
  30. Stiles B. G., Wilkins T. D. Clostridium perfringens iota toxin: synergism between two proteins. Toxicon. 1986;24(8):767–773. doi: 10.1016/0041-0101(86)90101-7. [DOI] [PubMed] [Google Scholar]
  31. Watkins P. A., Moss J. Effects of nucleotides on activity of a purified ADP-ribosyltransferase from turkey erythrocytes. Arch Biochem Biophys. 1982 Jun;216(1):74–80. doi: 10.1016/0003-9861(82)90189-8. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES